Yoonki Hong and Woo Jin Kim* Pages 79 - 87 ( 9 )
Lung cancer is the most common cancer and the leading cause of cancer-related morbidity and mortality worldwide. As early symptoms of lung cancer are minimal and non-specific, many pa-tients are diagnosed at an advanced stage. Despite a concerted effort to diagnose lung cancer early, no biomarkers that can be used for lung cancer screening and prognosis prediction have been established so far. As global DNA demethylation and gene-specific promoter DNA methylation are present in lung cancer, DNA methylation biomarkers have become a major area of research as potential alternative di-agnostic methods to detect lung cancer at an early stage. This review summarizes the emerging DNA methylation changes in lung cancer tumorigenesis, focusing on biomarkers for early detection and their potential clinical applications in lung cancer.
Non-small-cell lung cancer, DNA methylation, biomarker, epigenetic, tumorigenesis, hypomethylation.
Department of Internal Medicine, School of Medicine, Kangwon National University, Chuncheon, Department of Internal Medicine, School of Medicine, Kangwon National University, Chuncheon